Latest News

Keep up to date with all our latest investments, service offerings and news items.

Click here to view our latest media kit

  • March 20, 2019

    Almac Discovery and Elasmogen to Share Anti-ROR-1 VNAR Data at American Association of Cancer Annual Meeting

  • March 18, 2019

    Almac Discovery Showcases its Deubiquitinase Drug Discovery Expertise at the American Association of Cancer Research Annual Meeting in Atlanta

  • August 6, 2018

    VNAR Based Oncology Platform in development

  • July 5, 2018

    Dr. Xavier Jacq Appointed Vice President, Biology

  • April 23, 2018

    Latest developments in DUB inhibitors shared at Proteasome & Autophagy Congress

  • April 10, 2018

    Almac Discovery to Present at AACR 2018

  • January 29, 2018

    Research Highlighted in Nature Chemical Biology

  • December 4, 2017

    USP7 inhibitors from UbiPlexTM Platform published

  • September 4, 2017

    ALM201 Poster Presentation at 2017 ESMO Congress

  • July 3, 2017

    ALM201 – Orphan Drug Designation Granted in Ovarian Cancer

  • June 20, 2017

    Agreement with Debiopharm to Develop Novel Wee-1 Inhibitor

  • May 8, 2017

    Wee-1 kinase patent approval granted

  • February 14, 2017

    Therapy-resistant cancer tumors targeted with RCSI

  • May 30, 2016

    Diseases of the eye explored with McClay Foundation and UU

  • February 4, 2016

    Novel allosteric Akt inhibitor (ALM301) Patent Protection Secured

  • October 5, 2015

    European Patent Protection for ALM201 Secured

  • July 10, 2015

    Ubiquitin Specific Protease Collaboration with Genentech

  • September 4, 2013

    £13m Investment Cancer Research Initiatives with QUB

  • April 27, 2009

    Minister Praises Craigavon Life Sciences Firm’s Commitment to R&D

  • June 10, 2008

    Almac Group Launches Oncology Discovery Arm